Babies with bronchopulmonary dysplasia (BPD), a lung disorder that affects premature infants and can lead to pulmonary hypertension (PH), may require medications to help manage PH, but often stop requiring the drugs as they grow into toddlerhood, a study found. “Providers noted a decrease in prescriptions of PH medications…
News
The activity of a gene called RUNX1 may serve as a biological marker of processes that can lead to right heart failure in pulmonary arterial hypertension (PAH), a study reports. Progressive decline of the right ventricle, the chamber of the heart that pumps blood to the lungs, is a…
Elevated pulmonary vascular resistance (PVR), a measure of how difficult it is for blood to move from the heart to the lungs, was associated with a higher risk of poor outcomes in people with pulmonary hypertension (PH) due to left heart disease, a real-world study in Japan shows. The…
Data from smartphones and wearable devices may help with the early detection of idiopathic pulmonary arterial hypertension (IPAH), a rare lung disease with no known cause, a study suggests. Using up to eight years of data obtained via the My Heart Counts iOS app, device-derived data helped distinguish…
Building on positive data from an earlier study, Allrock Bio has dosed the first patients in a small clinical trial testing ROC-101, its oral treatment candidate for pulmonary hypertension (PH). The open-label Phase 2a ROCSTAR study (NCT07175038) is recruiting patients across the U.S., Canada, and Europe — including…
Children with pulmonary hypertension (PH) engage in fewer and shorter bouts of intense physical activity than their peers, according to a new study that measured data from sensors worn on the wrist. Moreover, kids with more severe PH generally had “worse physical testing,” as well as “a steeper decline…
The first participant has been enrolled in a two-part Phase 3 clinical trial testing IKT-001, Inhibikase Therapeutics’ experimental formulation of imatinib, in people with pulmonary arterial hypertension (PAH). The Phase 3 IMPROVE-PAH trial (NCT07365332) is expected to enroll nearly 500 adults with various forms of PAH, ages 18…
Patients with interstitial lung diseases (ILDs) who require supplemental oxygen are more than three times as likely to experience pulmonary hypertension (PH), according to new interim data from the PHINDER study. The findings reveal that this serious complication is frequently missed by doctors, who correctly identified PH in 60%…
Anumana‘s AI-enabled algorithm for the early detection of pulmonary hypertension (PH) has been cleared for use by the U.S. Food and Drug Administration (FDA). “The FDA clearance of our Pulmonary Hypertension algorithm is the result of rigorous clinical development and regulatory work, and it marks a meaningful step…
Treatment with CS1, a once-daily oral therapy being developed by Cereno Scientific, was found to be safe and well tolerated for people with pulmonary arterial hypertension (PAH), according to one-year data from an expanded access program (EAP). The EAP (NCT06321705), also known as compassionate use in the…
In a large clinical trial, treatment with Winrevair (sotatercept-csrk) significantly reduced pressure in the lungs’ blood vessels among adults with a form of pulmonary hypertension associated with heart failure, according to newly published data. The injection therapy, approved in the U.S. for…
A history of smoking was associated with worse survival outcomes in male patients with pulmonary arterial hypertension (PAH), according to a new study. The analysis found, however, that smoking history did not significantly affect survival in female PAH patients or in people with chronic thromboembolic pulmonary hypertension (CTEPH).
